11:40-12:00 Mandating structured reports Eric Loveday.

Slides:



Advertisements
Similar presentations
Implementing NICE guidance
Advertisements

Neoadjuvant therapy for Rectal cancer
Geraldine O’Dowd Consultant Pathologist NHS Lanarkshire 18 th November 2014 Colorectal Cancer Pathology: Impact of new guidelines for the laboratory.
Polyps – Where do they come from and what do you do with them?!
AJCC Staging Moments AJCC TNM Staging 7th Edition Rectal Case #3 Contributors: J. Milburn Jessup, MD Cancer Diagnosis Program, DCTD, NCI, Rockville, Maryland.
Multimodality Therapy of Rectal Cancer Robert D. Madoff, MD University of Minnesota.
Total Mesorectal Excision A Practical Guide. Total Mesorectal Excision Background Original description in 1982 Complete excision of the mesorectum Meticulous.
Role of colonoscopy in the treatment of malignant polyps Pathology of malignant colorectal polyps Assessing the risk of residual disease post-polypectomy.
March 2002 Outcomes in thyroid cancer: what factors are important? Information Projects Team Outcomes in thyroid cancer: what factors are important? NYCRIS.
AJCC Staging Moments AJCC TNM Staging 7th Edition Glottic Larynx Case #1 Contributors: Jatin P. Shah, MD Memorial Sloan-Kettering Cancer Center, New York,
Colon Cancer Basic Science 9/21/05. Colon and rectal neoplasms are characterized by: Consist of the third most common site of new cancer cases and deaths.
The LCA: Implementing a Quality Assurance and Informatics Strategy to Enhance Cancer Care Dr Shelley Dolan LCA Clinical Director.
Guidance on Cancer Services Improving Outcomes for People with Skin Tumours including Melanoma NICE Stateholder Consultation version July 2005.
CRITICAL READING OF THE LITERATURE RELEVANT POINTS: - End points (including the one used for sample size) - Surrogate end points - Quality of the performed.
AJCC TNM Staging 7th Edition Breast Case #3
Managing the patients experience of radical surgery with HIPEC for stage 4 colorectal disease Jackie Rodger Lead Colorectal Nurse Specialist Carol Baird.
Reporting and Management of Early stage Colorectal Cancer Frank Carey Dundee.
Management of early rectal carcinoma Joint Hospital Surgical Grand Round Jeren Lim United Christian Hospital.
Management of Locally Advanced Rectal Cancer Joint Hospital Surgical Grand Round Pamela Youde Nethersole Eastern Hospital Dr. YH Ling 19 May 2007.
AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #2 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.
How are we doing? Quality in Breast Cancer Care Dr Michelle Goecke Surgical Oncology Network Update October 18, 2014.
Guidelines for Prescribing
Rectal Cancer Alliance of Canada The webinar will begin shortly All participant lines will be muted during the presentation. Following the presentation,
Slides last updated: March 2015 CRC: STAGING. How colorectal cancer (CRC) is staged 1 Stage describes the extent of cancer, and is one of the most important.
Brendan Moran Basingstoke OCTOBER 2008
The Audit Process Tahera Chaudry March Clinical audit A quality improvement process that seeks to improve patient care and outcomes through systematic.
T4 Colon Cancer and Laparoscopic Approach Gustavo Plasencia MD FACS, FASCRS Clinical Professor of Surgery Gustavo Plasencia MD FACS, FASCRS Clinical Professor.
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain.
Current Role of Partial Cystectomy: Are we scarifying patient ’ s survival Dr Eric Li Department of Surgery Pamela Youde Nethersole hospital.
CR07 results and informed patient consent David Sebag-Montefiore Leeds Cancer Centre.
Preoperative chemoradiotherapy and postoperative chemotherapy with 5-FU and oxaliplatin versus 5-FU alone in locally advanced rectal cancer: First results.
Clinical Writing for Interventional Cardiologists.
Pathologist and Prognosis in Colorectal Cancer Surgery. Dr Bryan F Warren Consultant Gastrointestinal Pathologist Oxford M62 Course 2004.
Colon Cancer. Multihit Concept Clinical Information Clinical Information 1. Patient identification a. Name b. Identification number c. Age (birth date)
Enhanced biomedical scientist cut-up role in colonic carcinoma; preliminary performance data and comparison with departmental performance. E. J. V. Simmons*
Local recurrence after rectal cancer resection is strongly related to the plane of surgical (PoS) dissection and is further reduced by pre-operative short.
T Staging: Rectal cancer T1 invades submucosa T2 invades muscularis propria T3 invades subserosa or perirectal tissues T4 invades peritoneum, organs or.
EBM --- Journal Reading Presenter :呂宥達 Date : 2005/10/27.
Synchronous Metastasis on Staging/Surveillance CT chest abdomen & Pelvis + CEA + MRI Liver /PET-CT Synchronous Metastasis on Staging/Surveillance CT chest.
Collaborative Staging for Colon Site Specific Factors Tonya Brandenburg, MHA, CTR QA Manager Abstracting and Coding Kentucky Cancer Registry.
Preliminary Results of the MRC CR07 / NCIC CO16 Randomized Trial Short course pre-op vs selective post-op chemo-RT for rectal cancer Local Recurrence after.
Dr Mark Saunders Christie Hospital and Paterson Institute of Cancer Research “ Rectal cancer radiotherapy – why do we give it and how do we do it?”
Basingstoke Colorectal The Particular Problem of Low Rectal Cancer Brendan Moran Basingstoke 4 th East-West Colorectal Days Hungary 2008.
Role of MRI in Primary Rectal Cancer Staging and Management
Rectal cancer staging go the full “DISTANCE” Geertje Noë.
F/39 CC : Defecation difficulty D : 1mo. Sigmoidoscopy (10.3.2)
Annals of Oncology 24: 2206–2223, 2013 R3 조영학
Kyung Hee University, Seoul, Korea Conference LGI Conference Presented by Byeong-Joo Noh Supervised by Youn-Wha Kim Kyung Hee University, Seoul, Korea.
The Malignant Polyp Handout Version Hans Elzinga, MD Program Director- Advanced Procedures in Family Medicine Fellowship Salud Family Health Center-Longmont,
RECTAL CARCINOMA AND PREOPERATIVE MRI: USING A NATIONAL DATASET FOR REGIONAL AUDIT South West Cancer Intelligence Service J Weeks
Risk Stratification in Stage II Colon Cancer Patients Ramzi Amri, MD, PhD; Liliana G Bordeianou, MD, MPH; and David L Berger, MD Massachusetts General.
Professor Guram Karazanashvili MD, KMSc, DMSc MMT Hospital.
SMDT SMDT SMDT Synchronous Metastasis on Staging/Surveillance
Karcinom rektuma- management
Beyond TME : why do an exenteration?
Oesophago–Gastric Cancer
National Oesophago–Gastric Cancer Audit 2015.
Dr.Amit Gupta Associate Professor Dept. of Surgery
MRI: techniques for rectal cancer staging and standardisation
Magnetic Resonance Imaging of Anorectal Neoplasms
Dr Jessica Jenkins Consultant Oncologist
The BAHNO Head & Neck Cancer Surveillance Audit 2018
Principal recommendations
Making MDTs better Steve Falk
National Oesophago-Gastric Cancer Audit 2018 Annual Report: Slide set
The BAHNO Head & Neck Cancer Surveillance Audit 2018
Dr Rajayogeswaran Dr Mike Bradley
The STAR-TREC Trial SIV Presentation
Changes in TNM 8 To be used from
Developments in Colorectal Cancer
Presentation transcript:

11:40-12:00 Mandating structured reports Eric Loveday

Clinical History : CTC shows annular tumour of the mid rectum extending craniocaudally for approx 4.7cm. for staging MRI please Requested By: Annie Reilly CNS Bleep: DWI affected by large amount of metal work in leg. Unable to keep still due to cramp in legs, ordinarily doesn't lie on back much. MRI Pelvis Rectum : As per radiographer comment above the image quality, particularly on the critical small field of view images and the DWI is of very poor quality. Primary Tumour: Annular Height from anal verge: 96mm Distal edge lies: 68 mm above the puborectalis sling Extends craniocaudally over 50 mm Lies below the peritoneal reflection Invading edge of tumour from 12 o'clock to 4 o'clock. Muscularis Propria: Extends through Extramural spread 3-4mm T stage: T3b The tumour is of annular configuration with high signal elements within it indicating mucinous differentiation. The degree of extra mural spread is very difficult to ascertain accurately given the limitations described above but is favoured to represent a full-thickness extramural disease with less than 5 mm of measurable spread. There is a bulging mucinous focus at approximately 1 o'clock but this does not appear to breach the outer layer of the muscularis propria. The tumour is well clear of the circumflex resection margin. Lymph nodes: No overt pathological nodes. Extramural venous invasion: No overt evidence. Closest circumferential resection margin 3 o'clock. Closest circumferential resection motion is from direct spread of tumour. Minimum tumour distance to mesorectal fascia: 22 mm. CRM clear. Peritoneal deposits: No evidence Pelvic sidewall lymph nodes: None Summary: MRI overall stage: Mid rectal tumour. T3b N0 Mx. CRM clear. EMVI negative. Mucinous differentiation. No adverse features - eligible for primary surgery. Comment: Poor quality study with low diagnostic confidence for accurate T staging and EMVI status but no indication for preoperative downstaging.

Clinical History : post long course for rectal cancer. MRI to assess response to treatment. Requested By: Annie Reilly CNS Bleep: MRI Pelvis Rectum : (Structured report) >75% fibrosis, minimal tumour signal tumour intensity, TRG2 Height from anal verge: 66 mm Treated tumour distal edge lies: 38 mm above the puborectalis sling Extends craniocaudally over 50 mm Lies below the peritoneal reflection Invading edge of tumour from 7 o'clock to 12 o'clock. Tumour signal extends through the muscularis propria Fibrotic signal extends through the muscularis propria Extramural spread 7mm for tumour signal 8mm for fibrotic stroma. yMR T stage:T3c Low rectal tumour: -Into intersphincteric plane: Intersphincteric plane/mesorectal plane is unsafe, extra levator APE. Lymph nodes: Non- Extramural venous invasion: No evidence Closest circumferential resection margin 11 o'clock. Closest circumferential resection margin is from direct spread of tumour Minimum tumour distance to mesorectal fascia: 0 mm. CRM is involved. Peritoneal deposits: No evidence Pelvic sidewall lymph nodes: None Summary: yMRI overall stage: ymrT3c ymrN0 ymrMx. TRG 2 CRM is involved. EMVI negative Comment: Unfortunately the scan is being performed on a different scanner to the original. Good quality study notwithstanding. Much of the tumour signal is replaced by fibrosis. There are mucin lakes in the submucosa layer which have increased in size in the interval. There is intermediate signal material anteriorly in contact with the posterior aspect of the medial right seminal vesicle (image 21 series 5.) Treated tumour is in contact with the lateral circumferential resection margin and in the intersphincteric plane (image 14 series 6). No definite vascular involvement on these scans.

Each dataset contains core data items that are mandated for inclusion in the Cancer Outcomes and Services Dataset (COSD – previously the National Cancer Dataset) in England. Core data items are items that are supported by robust published evidence and are required for cancer staging, optimal patient management and prognosis. Core data items meet the requirements of professional standards (as defined by the Information Standards Board for Health and Social Care [ISB]) and it is recommended that at least 90% of reports on cancer resections should record a full set of core data items. Other, non-core, data items are described. These may be included to provide a comprehensive report or to meet local clinical or research requirements. All data items should be clearly defined to allow the unambiguous recording of data.

The cancer datasets published by The Royal College of Pathologists (RCPath) are a combination of textual guidance guidance, educational information and reporting proformas. The datasets enable pathologists to grade and stage cancers in an accurate, consistent manner in compliance with international standards and provide prognostic information, thereby allowing clinicians to provide a high standard of care for patients and appropriate management for specific clinical circumstances. It may rarely be necessary or even desirable to depart from the guidelines in the interests of specific patients and special circumstances. The clinical risk of departing from the guidelines should be assessed by the relevant multidisciplinary team (MDT); just as adherence to the guidelines may not constitute defence against a claim of negligence, so a decision to deviate from them should not necessarily be deemed negligent.

Potential benefits of structured reporting Consistency Quality Compliance Comparability Supports research Improved outcomes Use of existing tools